Skip to main content
SpringerLink
Log in

Acute Pulmonary Infiltrates in Patients with Rheumatoid Arthritis: Differential Diagnosis and Management

  • Chapter
  • First Online:
Lung Disease Associated with Rheumatoid Arthritis

Abstract

Patients with rheumatoid arthritis (RA) sometimes experience acute onset of respiratory symptoms with pulmonary infiltrates on chest roentgenogram, potentially leading to respiratory failure. Because many of RA patients have pre-existing lung complications, such as interstitial lung disease (ILD) and airway disease, and receive various immune-modulating drugs, it is often difficult to make a correct diagnosis. The differential diagnosis includes acute exacerbation of RA-associated ILD, drug-induced occurrence or exacerbation of ILD, and respiratory infection. There are many diagnostic tools, such as radiological examination, laboratory tests, bronchoalveolar lavage, and lung biopsy, but, in most cases, none of these tools has enough power to make a diagnosis by itself, requiring a combined diagnostic approach. Once an RA patient is diagnosed with acute exacerbation of ILD or rapidly progressive ILD, ventilatory management and drug treatment should be initiated immediately in accordance with those of acute exacerbation of idiopathic interstitial pneumonias. In case of bacterial pneumonia in RA patients receiving immune-modulating agents, it should be treated as healthcare-associated pneumonia, considering risk factor for Pseudomonas aeruginosa infection. Pneumocystis jirovecii pneumonia in RA patients is characterized by an abrupt onset of respiratory insufficiency, requiring a speedy diagnosis using PCR and serum β-D-glucan measurement.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Turesson C, Jacobsson L, Bergström U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology. 1999;38(7):668–74.

    Article  CAS  PubMed  Google Scholar 

  2. Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21(1):33–6.

    CAS  PubMed  Google Scholar 

  3. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(2):628–34.

    Article  CAS  PubMed  Google Scholar 

  4. Herrinton LJ, Harrold LR, Liu L, Raebel MA, Taharka A, Winthrop KL, et al. Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf. 2013;22(4):394–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mori S, Cho I, Koga Y, Sugimoto M. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol. 2008;35(8):1513–21.

    PubMed  Google Scholar 

  6. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636–43.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med. 2009;103(6):846–53.

    Article  PubMed  Google Scholar 

  8. Papiris SA, Manali ED, Kolilekas L, Kagouridis K, Triantafillidou C, Tsangaris I, et al. Clinical review: idiopathic pulmonary fibrosis acute exacerbations—unravelling Ariadne’s thread. Crit Care. 2010;14(6):246.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kinoshita F, Hamano H, Harada H, Kinoshita T, Igishi T, Hagino H, et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med. 2004;98(11):1131–7.

    Article  PubMed  Google Scholar 

  10. Nakajima H, Harigai M, Hara M, Hakoda M, Tokuda H, Sakai F, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27(5):1164–70.

    CAS  PubMed  Google Scholar 

  11. Horio Y, Takihara T, Niimi K, Komatsu M, Sato M, Tanaka J, et al. High-flow nasal cannula oxygen therapy for acute exacerbation of interstitial pneumonia: a case series. Respir Investig. 2016;54(2):125–9.

    Article  PubMed  Google Scholar 

  12. Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132(1):214–20.

    Article  PubMed  Google Scholar 

  13. Toyoda Y, Hanibuchi M, Kishi J, Kawano H, Morizumi S, Sato S, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. J Med Investig. 2016;63(3–4):294–9.

    Article  Google Scholar 

  14. Libby D, White DA. Pulmonary toxicity of drugs used to treat systemic autoimmune diseases. Clin Chest Med. 1998;19(4):809–21.

    Article  CAS  PubMed  Google Scholar 

  15. Jani M, Hirani N, Matteson EL, Dixon WG. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol. 2014;10(5):284–94.

    Article  CAS  PubMed  Google Scholar 

  16. Obadina ET, Torrealba JM, Kanne JP. Acute pulmonary injury: high-resolution CT and histopathological spectrum. Br J Radiol. 2013;86(1027):20120614.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Tsujimoto K, Hata A, Fujita M, Hatachi S, Yagita M. Presepsin and procalcitonin as biomarkers of systemic bacterial infection in patients with rheumatoid arthritis. Int J Rheum Dis. 2016. https://doi.org/10.1111/1756-185X.12899.

  18. Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. 2007;131(4):1173–80.

    Article  CAS  PubMed  Google Scholar 

  19. Miyata M, Sakuma F, Fukaya E, Kobayashi H, Rai T, Saito H, et al. Detection and monitoring of methotrexate-associated lung injury using serum markers KL-6 and SP-D in rheumatoid arthritis. Intern Med. 2002;41(6):467–73.

    Article  PubMed  Google Scholar 

  20. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809–20.

    Article  CAS  PubMed  Google Scholar 

  21. Matsuno O, Okubo T, Hiroshige S, Takenaka R, Ono E, Ueno T, et al. Drug-induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia. Tohoku J Exp Med. 2007;212(1):49–53.

    Article  PubMed  Google Scholar 

  22. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Müller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol. 2002;57(4):292–9.

    Article  PubMed  Google Scholar 

  23. Padley SP, Adler B, Hansell DM, Müller NL. High-resolution computed tomography of drug-induced lung disease. Clin Radiol. 1992;46(4):232–6.

    Article  CAS  PubMed  Google Scholar 

  24. Akira M, Ishikawa H, Yamamoto S. Drug-induced pneumonitis: thin-section CT findings in 60 patients. Radiology. 2002;224(3):852–60.

    Article  PubMed  Google Scholar 

  25. Ellis SJ, Cleverley JR, Müller NL. Drug-induced lung disease: high-resolution CT findings. AJR Am J Roentgenol. 2000;175(4):1019–24.

    Article  CAS  PubMed  Google Scholar 

  26. Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med. 2004;25(1):25–35.

    Article  PubMed  Google Scholar 

  27. Akoun GM, Cadranel JL, Milleron BJ, D'Ortho MP, Mayaud CM. Bronchoalveolar lavage cell data in 19 patients with drug-associated pneumonitis (except amiodarone). Chest. 1991;99(1):98–104.

    Article  CAS  PubMed  Google Scholar 

  28. Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med. 2004;25(1):37–45.

    Article  PubMed  Google Scholar 

  29. Camus P. The Drug-Induced Respiratory Disease Website. www.pneumotox.com. Accessed 7 Jan 2017.

  30. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613–26.

    Article  CAS  PubMed  Google Scholar 

  31. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4(4):723–30.

    Article  CAS  PubMed  Google Scholar 

  32. Saravanan V, Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(7):787–9.

    Article  CAS  Google Scholar 

  33. Cavagna L, Monti S, Grosso V, Boffini N, Scorletti E, Crepaldi G, et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int. 2013;2013:759760.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AM, van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis. 1994;53(7):434–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Tokuda H, Sakai F, Yamada H, Johkoh T, Imamura A, Dohi M, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med. 2008;47(10):915–23.

    Article  PubMed  Google Scholar 

  36. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15(2):373–81.

    Article  CAS  PubMed  Google Scholar 

  37. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol. 1987;14(6):1164–71.

    CAS  PubMed  Google Scholar 

  38. Leth-Larsen R, Nordenbaek C, Tornoe I, Moeller V, Schlosser A, Koch C, et al. Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia. Clin Immunol. 2003;108(1):29–37.

    Article  CAS  PubMed  Google Scholar 

  39. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology. 2005;44(1):61–6.

    Article  CAS  PubMed  Google Scholar 

  40. Picchianti Diamanti A, Germano V, Bizzi E, Laganà B, Migliore A. Interstitial lung disease in rheumatoid arthritis in the era of biologics. Pulm Med. 2011;2011:931342.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Roubille C, Martel-Pelletier J, Haraoui B, Tardif JC, Pelletier JP. Biologics and the cardiovascular system: a double-edged sword. Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):68–82.

    Article  CAS  PubMed  Google Scholar 

  42. Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJ. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases—a systematic literature review. Rheumatology (Oxford). 2011;50(12):2297–305.

    Article  Google Scholar 

  43. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189–94.

    Article  CAS  PubMed  Google Scholar 

  44. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and efectiveness of etanercept in Japan. J Rheumatol. 2009;36(5):898–906.

    Article  CAS  PubMed  Google Scholar 

  45. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2012;22(4):498–508.

    Article  CAS  PubMed  Google Scholar 

  46. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70(12):2148–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41(2):256–64.

    Article  CAS  PubMed  Google Scholar 

  48. Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319.

    Google Scholar 

  49. Kawashiri SY, Kawakami A, Sakamoto N, Ishimatsu Y, Eguchi K. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int. 2012;32(12):4023–6.

    Article  PubMed  Google Scholar 

  50. Lager J, Hilberg O, Løkke A, Bendstrup E. Severe interstitial lung disease following treatment with certolizumab pegol: a case report. Eur Respir Rev. 2013;22(129):414–6.

    Article  PubMed  Google Scholar 

  51. Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007;34(5):1151–4.

    PubMed  Google Scholar 

  52. Sen S, Peltz C, Jordan K, Boes TJ. Infliximab-induced nonspecific interstitial pneumonia. Am J Med Sci. 2012;344(1):75–8.

    Article  PubMed  Google Scholar 

  53. Nakashita T, Motojima S, Fujio N, Jibatake A. The incidence of exacerbation of pre-existing interstitial lung disease (ILD) is higher in TNF blockers than in non-TNF blockers in RA. Arthritis Rheum. 2012;64(Suppl 10):1332. https://doi.org/10.1002/art.39064.

    Google Scholar 

  54. Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X, BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med. 2011;124(5):386–94.

    Article  CAS  PubMed  Google Scholar 

  55. Harigai M, Takamura A, Atsumi T, Dohi M, Hirata S, Kameda H, et al. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs. Mod Rheumatol. 2013;23(2):284–96.

    Article  CAS  PubMed  Google Scholar 

  56. de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8(1):53–82.

    Article  PubMed  Google Scholar 

  57. Hallowell RW, Horton MR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs. 2014;74(4):443–50.

    Article  CAS  PubMed  Google Scholar 

  58. Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Yoshida Y, et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med. 2011;50(4):305–13.

    Article  CAS  PubMed  Google Scholar 

  59. Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69(6):1086–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Coyne P, Doe S, Saravanan V, Heycock C, Hamilton J, Kelly CA. Is respiratory infection in patients with rheumatoid arthritis caused by disease modifying drugs? Rheumatology. 2005;i74(A42):44.

    Google Scholar 

  61. Takayanagi N. Biological agents and respiratory infections: causative mechanisms and practice management. Respir Investig. 2015;53(5):185–200.

    Article  PubMed  Google Scholar 

  62. Coyne P, Hamilton J, Heycock C, Saravanan V, Coulson E, Kelly CA. Acute lower respiratory tract infection in patients with rheumatoid arthritis. J Rheumatol. 2007;34(9):1832–6.

    CAS  PubMed  Google Scholar 

  63. Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection inpatients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther. 2011;13(4):R139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3(3):148–55.

    Article  CAS  PubMed  Google Scholar 

  66. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–104.

    Article  CAS  PubMed  Google Scholar 

  67. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol. 2011;38(7):1258–64.

    Article  CAS  PubMed  Google Scholar 

  68. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial diseases and antitumour necrosis factor therapy in the USA. Ann Rheum Dis. 2013;72(1):37–42.

    Article  CAS  PubMed  Google Scholar 

  69. Macfarlane JT, Boldy D. 2004 update of BTS pneumonia guidelines: what’s new? Thorax. 2004;59(5):364–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Takayanagi N, Tsuchiya Y, Tokunaga D, Miyahara Y, Yamaguchi S, Saito H, et al. [Pulmonary infections in patients with rheumatoid arthritis]. Nihon Kokyuki Gakkai Zasshi. 2007;45(6):465–73.

    Google Scholar 

  71. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population based study. Arthritis Rheum. 2002;46(9):2287–93.

    Article  PubMed  Google Scholar 

  72. Nakajima A, Saito K, Kojima T, Amano K, Yoshio T, Fukuda W, et al. No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Mod Rheumatol. 2013;23(5):945–52.

    Article  CAS  PubMed  Google Scholar 

  73. Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5(6):729–35.

    Article  PubMed  Google Scholar 

  74. Tubach F, Ravaud P, Salmon-Céron D, Petitpain N, Brocq O, Grados F, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor–α antagonists. Clin Infect Dis. 2006;43(10):e95–100.

    Article  CAS  PubMed  Google Scholar 

  75. Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol. 2009;19(1):64–8.

    Article  PubMed  Google Scholar 

  76. Gaensbauer JT, Press CA, Hollister JR, Asturias EJ. Procalcitonin: a marker of infection not subverted by treatment with interleukin-6 receptor inhibition. Pediatr Infect Dis J. 2013;32(9):1040.

    Article  PubMed  Google Scholar 

  77. Tokuda H, Harigai M, Kameda H, Tomono K, Takayanagi N, Watanabe A, et al. Consensus statements for medical practice: biological agents and lung disease. Respir Investig. 2017;55(3):229–51.

    Article  PubMed  Google Scholar 

  78. Takayanagi N, Hara K, Tokunaga D, Takaku Y, Minagawa S, Tsuchiya Y, et al. [Etiology and outcome of community-acquired pneumonia in relation to age and severity in hospitalized adult patients]. Nihon Kokyuki Gakkai Zasshi. 2006;44(12):906–15.

    Google Scholar 

  79. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42(4):780–9.

    Article  CAS  PubMed  Google Scholar 

  80. Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis. 2011;5(1):41–59.

    Article  CAS  PubMed  Google Scholar 

  81. Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother. 2012;18(6):793–806.

    Article  CAS  PubMed  Google Scholar 

  82. Mekinian A, Durand-Joly I, Hatron PY, Moranne O, Denis G, Dei-Cas E, et al. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology. 2011;50(3):569–77.

    Article  PubMed  Google Scholar 

  83. Wissmann G, Morilla R, Martín-Garrido I, Friaza V, Respaldiza N, Povedano J, et al. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur J Clin Investig. 2011;41(3):343–8.

    Article  CAS  Google Scholar 

  84. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis. 2008;197(1):10–7.

    Article  CAS  PubMed  Google Scholar 

  85. Mori S, Cho I, Sugimoto M. A follow-up study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol. 2009;36(8):1600–5.

    Article  CAS  PubMed  Google Scholar 

  86. Tasaka S, Kobayashi S, Kamata H, Kimizuka Y, Fujiwara H, Funatsu Y, et al. Cytokine profiles of bronchoalveolar lavage fluid in patients with Pneumocystis pneumonia. Microbiol Immunol. 2010;54(7):425–33.

    CAS  PubMed  Google Scholar 

  87. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100(5):663–71.

    Article  CAS  PubMed  Google Scholar 

  88. Kuhlman JE, Kavuru M, Fishman EK, Siegelman SS. Pneumocystis carinii pneumonia: spectrum of parenchymal CT findings. Radiology. 1990;175(3):711–4.

    Article  CAS  PubMed  Google Scholar 

  89. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother. 2007;13(1):1–7.

    Article  PubMed  Google Scholar 

  90. Reid AB, Chen SC, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis. 2011;24(6):534–44.

    Article  CAS  PubMed  Google Scholar 

  91. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1–207.

    Google Scholar 

  92. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357(18):1874–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan

    Sadatomo Tasaka M.D.

Authors
  1. Sadatomo Tasaka M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sadatomo Tasaka M.D. .

Editor information

Editors and Affiliations

  1. Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Takahisa Gono

  2. Department of Respiratory Medicine, JCHO Tokyo Yamate Medical Center, Tokyo, Japan

    Hitoshi Tokuda

  3. Department of Diagnostic Radiology, Saitama International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan

    Fumikazu Sakai

  4. Department of Pathology , Japanese Red Cross Medical Center, Tokyo, Japan

    Tamiko Takemura

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tasaka, S. (2018). Acute Pulmonary Infiltrates in Patients with Rheumatoid Arthritis: Differential Diagnosis and Management. In: Gono, T., Tokuda, H., Sakai, F., Takemura, T. (eds) Lung Disease Associated with Rheumatoid Arthritis. Springer, Singapore. https://doi.org/10.1007/978-981-10-6750-1_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-6750-1_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-6749-5

  • Online ISBN: 978-981-10-6750-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation